Stuttgart - Delayed Quote EUR

Agios Pharmaceuticals Inc (8AP.SG)

24.80

-0.20

(-0.80%)

As of 8:03:55 AM GMT+2. Market Open.

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company’s PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. “The clinical results and scientific insights being

GlobeNewswire 20 hours ago

AGIO
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders

We didn't see Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) stock surge when it reported robust earnings recently. We...

Simply Wall St. 5 days ago

AGIO
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A re

GlobeNewswire 5 days ago

AGIO
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

Zacks 12 days ago

AGIO
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A

GlobeNewswire 12 days ago

AGIO
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Agios Pharmaceuticals Inc (AGIO) reports a 6% revenue increase and outlines promising pipeline developments, despite facing revenue and expense challenges.

GuruFocus.com 13 days ago

AGIO
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 13.89% and 11.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 13 days ago

AGIO
Agios Pharmaceuticals: Q1 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Agios Pharmaceuticals Inc. AGIO) on Thursday reported a loss of $89.3 million in its first quarter.

Associated Press Finance 14 days ago

AGIO
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable

GlobeNewswire 14 days ago

AGIO
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 20 days ago

AGIO

SAGE
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) un

GlobeNewswire 27 days ago

AGIO
New Strong Sell Stocks for April 3rd

AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.

Zacks last month

AGIO

CHGG

EFX
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks last month

WVE

AGIO
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?

We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against other best small-cap stocks to buy before they explode. Is Market Volatility Good For Small-Cap Stocks? Since the announcement of tariffs, investors […]

Insider Monkey last month

AGIO
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company’s 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants were approved by the Board of Directors effective as of March 5, 2025, as inducements

GlobeNewswire 2 months ago

AGIO
Agios to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m. ETBarclays 27th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 12, 2025, at 12:30 p.m. ET The l

GlobeNewswire 2 months ago

AGIO
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other small-cap stocks. The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year […]

Insider Monkey 2 months ago

AGIO

^GSPC

^RUT
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of t

GlobeNewswire 2 months ago

AGIO
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company’s regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat’s point of sickening. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia

TipRanks 2 months ago

AGIO
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.

Zacks 2 months ago

AGIO

Performance Overview

Return	8AP.SG	S&P 500 (^GSPC)
YTD	-21.52%	+0.19%
1-Year	-22.50%	+11.01%
3-Year	+20.39%	+46.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agios Pharmaceuticals Inc (8AP.SG)

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

New Strong Sell Stocks for April 3rd

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Performance Overview